- Home
- Programs and Groups
- Shared Resources
- Faculty
- Clinical Trials
- Tumor Registry
- Education
- About DCI
Quick Links
Adult Clinical Trials - Breast Cancer
If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Kim Riley at 919-660-1278.
Items 1 - 21 of 21
Items 1 - 21 of 21
Breast Cancer Working Group (BCWG)
Triple Negative Metastatic Breast Cancer Tissue Repository (TNMBC-TR)
Principal Investigator: Kimberly Blackwell
Phase: N/A
Phone: 919-660-1278
Principal Investigator: Kimberly Blackwell
Phase: N/A
Phone: 919-660-1278
A PHASE II STUDY OF ABRAXANE®, AND CARBOPLATIN AS FIRST LINE TREATMENT FOR "TRIPLE NEGATIVE" (DEMONSTRATING NO EXPRESSION FOR ESTROGEN, PROGESTERONE, OR HER2 RECEPTORS) METASTATIC BREAST CANCER
Principal Investigator: Kimberly Blackwell
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Kimberly Blackwell
Phase: Phase II
Phone: 919-660-1278
A Phase II Trial of HKI-272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases (TBCRC 022)
Principal Investigator: Kimberly Blackwell
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Kimberly Blackwell
Phase: Phase II
Phone: 919-660-1278
Randomized, Open-Label Study of Abiraterone Acetate (JNJ 212082) Alone or in Combination with Exemestane in
Postmenopausal Women with ER+Metastatice Breast Cancer Progressing during or after Letrozole or Anastrozole Therapy
Principal Investigator: Kimberly Blackwell
Phase: Phase III
Phone: 919-660-1278
Principal Investigator: Kimberly Blackwell
Phase: Phase III
Phone: 919-660-1278
The BEACON Study (BrEAst Cancer Outcomes with NKTR-102):
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physicians Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane, and Capecitabine
Principal Investigator: Kimberly Blackwell
Phase: Phase III
Phone: 919-660-1278
Principal Investigator: Kimberly Blackwell
Phase: Phase III
Phone: 919-660-1278
CALGB 70806: Vitamin D and Breast Cancer Biomarkers
Principal Investigator: Jeffrey Crawford
Phase: N/A
Phone: 919-970-1551
Principal Investigator: Jeffrey Crawford
Phase: N/A
Phone: 919-970-1551
CALGB 40903: Phase II Study of Neoadjuvant Letrozole for Postmeopausal Women with Estrogen Receptor Positive Ducal Carcinoma In Situ (DCIS)
Principal Investigator: Jeffrey Crawford
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Jeffrey Crawford
Phase: Phase II
Phone: 919-660-1278
CTSU NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Principal Investigator: Jeffrey Crawford
Phase: Phase III
Phone: 919-419-4631
Principal Investigator: Jeffrey Crawford
Phase: Phase III
Phone: 919-419-4631
CTSU SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Principal Investigator: Jeffrey Crawford
Phase: Phase III
Principal Investigator: Jeffrey Crawford
Phase: Phase III
AeroForm Patient Activated Controlled Tissue Expander System for Breast Reconstruction
Principal Investigator: Scott Hollenbeck
Phase: N/A
Principal Investigator: Scott Hollenbeck
Phase: N/A
Pilot study of General Well-being, Cardiovascular Status and Left
Ventricular Function in Women Treated with Anthracycline
Containing Chemotherapy for Operable Breast Cancer
Principal Investigator: Lee Jones
Phase: Phase III
Phone: 919-684-5494
Principal Investigator: Lee Jones
Phase: Phase III
Phone: 919-684-5494
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Aged 60 or Older wit HER2 Positive Metastatic Breast Cancer
Principal Investigator: Gretchen Kimmick
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Gretchen Kimmick
Phase: Phase II
Phone: 919-660-1278
TBCRC 023: A RANDOMIZED MULTICENTER PHASE II NEOADJUVANT TRIAL OF LAPATINIB PLUS TRASTUZUMAB, WITH OR WITHOUT ENDOCRINE THERAPY, FOR 12 WEEKS VS. 24 WEEKS IN PATIENTS WITH HER2 OVEREXPRESSING BREAST CANCER
Principal Investigator: Nicole Kuderer
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Nicole Kuderer
Phase: Phase II
Phone: 919-660-1278
LCCC 1024: Phase I Dose-Escalation Study of Concurrent BKM120 and Capecitabine or Concurrent BEZ235 and Capecitabine in Patients with Metastatic Breast Cancer
Principal Investigator: P. Kelly Marcom
Phase: Phase I
Principal Investigator: P. Kelly Marcom
Phase: Phase I
A Phase Ib/II, open label, multi-center study evaluating the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previously failed trastuzumab
Principal Investigator: P. Kelly Marcom
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: P. Kelly Marcom
Phase: Phase II
Phone: 919-660-1278
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Principal Investigator: P. Kelly Marcom
Phase: Phase II
Principal Investigator: P. Kelly Marcom
Phase: Phase II
A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer
Principal Investigator: Jeffrey Peppercorn
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Jeffrey Peppercorn
Phase: Phase II
Phone: 919-660-1278
Investigation of Genetic Determinants of Capecitabine Toxicity
Principal Investigator: Jeffrey Peppercorn
Phase: Phase III
Phone: 919-660-1278
Principal Investigator: Jeffrey Peppercorn
Phase: Phase III
Phone: 919-660-1278
Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Principal Investigator: Victoria Seewaldt
Phase: N/A
Principal Investigator: Victoria Seewaldt
Phase: N/A
An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib (STA-9090) Monotherapy in Women with Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer
Principal Investigator: Neil Spector
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Neil Spector
Phase: Phase II
Phone: 919-660-1278
An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing inflammatory breast cancer
Principal Investigator: Neil Spector
Phase: Phase II
Phone: 919-660-1278
Principal Investigator: Neil Spector
Phase: Phase II
Phone: 919-660-1278
